News By Tag
News By Location
Journal of Commercial Biotechnology: New issue now available
The November 2011 issue of the Journal of Commercial Biotechnology is now available.
Journal of Commercial Biotechnology Vol 17, Issue 4 (2011)
New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health?
Biotechnology companies can play an important role in advancing technologies for global health. Initiatives such as Genzyme’s Humanitarian Assistance for Neglected Diseases and Alnylam’s Intellectual Property (IP) contributions to the Pool for Open Innovation against Neglected Tropical Diseases show a commitment to helping produce badly needed health technologies, but unmet needs for new drugs, vaccines and diagnostics for diseases affecting developing countries remain…
Biotechnology commercialisation in universities of developing countries: A review of the University of Ibadan, Nigeria
Chimdiya Julian Onyeka
The British colonial administration established the University of Ibadan (UI) in 1948 as an extension of the University College London and it became Nigeria’s first full-fledged and premier university in 1962. The university comprises 13 faculties and a distance learning programme. Among the university’s faculties is one for Science, one for Technology and another for Agriculture and Forestry…
Innovation in R&D: Using design thinking to develop new models of inventiveness, productivity and collaboration
Tad Simons, Arvind Gupta, Mary Buchanan
By adapting insights and methodologies from design thinking, a modern scientific R&D organization may have the potential to increase the speed, inventiveness and vitality of their output and become an explosive engine of growth. Modern design consultancies face the challenge of producing original, creative work for their clients on project after project, and have thus developed several strategies and behaviors to produce innovative content repeatedly at a fast pace…
The strength of pharmaceutical IPRs vis-à-vis foreign direct investment in clinical research: Preliminary findings
Meir Perez Pugatch, Rachel Chu
This article examines the effect of the intellectual property (IP) environment in developing countries on the level of foreign direct investment (FDI) and technology transfer occurring in the biopharmaceutical field in these countries. In particular, it considers the correlation between the strength of IP protection in several developing countries (using the Pharmaceutical IP Index) and the number of clinical trials taking place in these countries (as a proxy of biomedical FDI)…
Some considerations for the implementation of disposable technology and single-use systems in biopharmaceuticals
Tim Sandle, Madhu Raju Saghee
This article, written from an industry perspective, examines the current trend towards the implementation of single-use disposable technologies in the biopharmaceutical and biotechnology sectors. Single-use technologies are generally sterile, plastic disposable items implemented to replace traditional pharmaceutical processing items that require recycling, cleaning and in-house sterilisation…
Catalyzing capital for Canada’s life sciences industry
Joseph Tucker, Justin Chakma, Paul WM Fedak, Massimo Cimini
Canada’s biotech sector ranks within the top five globally, but its life sciences venture capital (VC) industry is among the worlds weakest. This makes for an interesting case study in understanding the disconnect between low levels of VC and a healthy innovation ecosystem in terms of R&D spending, skilled workforce and enterprise support…
Academic entrepreneurship, entrepreneurial universities and biotechnology
Arlen D Meyers, Sarika Pruthi
There are various definitions of an entrepreneurial university, yet there is a lack of agreement about its core components. This article defines the five key characteristics of an entrepreneurial university based on examples of successful bio-clusters in the United States and Europe, and suggests an agenda for stakeholders…
Patent strategies for life sciences companies to navigate the changing patent landscape
David J Dykeman, Danielle T Abramson
As a result of the global recession that began in 2008, life sciences companies face a groundswell of new business and regulatory pressures that includes health care and patent reform, increased pricing pressures, and diluted markets. Bringing new products from discovery to market is becoming more expensive and unpredictable…
FDA at BIO 2011 – Weighing a hefty mission: Where is the balance?
The mission of the Food and Drug Administration (FDA) is to promote public health by ensuring the safety and quality of food and medical products sold in the United States. At this year’s annual Biotechnology Industry Organization (BIO) convention, significant discussion revolved around the appropriate interpretation and execution of that mission…
For more information, see the Journal of Commercial Biotechnology at http://CommercialBiotechnology.com
# # #
The Journal of Commercial Biotechnology is a quarterly peer-reviewed professional journal which focuses on the commercial, legal, and regulatory issues affecting biotechnology, biopharmaceutical, agrochemical, and environmental companies.